Pharminent · Daily Brief
October 12, 2026
Regulatory & Approvals
FDA approves Asahi Kasei’s Hovilpri for refractory HSV lesions
The US FDA has approved Asahi Kasei Therapeutics’ Hovilpri 100mg tablets for the treatment of refractory mucocutaneous herpes simplex virus lesions in immunocompromised adults.
Pharmaceutical Technology →
Clinical Data
Study shows Lilly’s Taltz works better combined with Zepbound
A study showed that the efficacy of Lilly’s psoriasis therapy Taltz is improved when given in combination with the weight-loss drug Zepbound.
Pharmaphorum →$LLY
Deals & Partnerships
Perceptive Discovery, Nucleus RadioPharma form radiopharmaceutical development partnership
Perceptive Discovery and Nucleus RadioPharma announced a non-exclusive strategic partnership to support radiopharmaceutical developers from initial target validation through clinical manufacturing.
Pharmaceutical Technology →
Forwarded this? Get your copy free
Sign up free →
Pharminent — Competitive Intelligence Suite · Tickers link to Yahoo Finance for reference only. Editorial framings are analysis, not investment advice. © 2026.